Maria Helena Raquel

Dr. Maria Helena Raquel


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Immunity
Verified
Journal Article
Closed access
NFNuno Figueiredo
Nuno Figueiredo
ACAngelo Chora
Angelo Chora
MRMaria Helena Raquel
Maria Helena Raquel
NPNadja Pejanovic
Nadja Pejanovic
PPPedro Pereira
Pedro Pereira
LMLuis Moita
Luis Moita

25 March 2010 in Blood
Verified
Journal Article
Closed access
PDF file
TLTelma Lança
Telma Lança
DCDaniel V. Correia
Daniel V. Correia
CMCatarina Ferreira Moita
Catarina Ferreira Moita
MRMaria Helena Raquel
Maria Helena Raquel
ACAna Neves Costa
Ana Neves Costa
BSBruno Silva-Santos
Bruno Silva-Santos
On the path to successful immunotherapy of hematopoietic tumors, γδ T cells offer great promise because of their human leukocyte antigen (HLA)–unrestricted targeting of a wide variety of leukemias/lymphomas. However, the molecular mechanisms underlying lymphoma recognition by γδ T cells remain unclear. Here we show that the expression levels of UL16-binding protein 1 (ULBP1) determine lymphoma susceptibility to γδ T cell–mediated cytolysis. Consistent with this, blockade of NKG2D, the receptor for ULBP1 expressed on all Vγ9+ T cells, significantly inhibits lymphoma cell killing. Specific loss-of-function studies demonstrate that the role of ULBP1 is nonredundant, highlighting a thus far unique physiologic relevance for tumor recognition by γδ T cells. Importantly, we observed a very wide spectrum of ULBP1 expression levels in primary biopsies obtained from lymphoma and leukemia patients. We suggest this will impact on the responsiveness to γδ T cell–based immunotherapy, and therefore propose ULBP1 to be used as a leukemia/lymphoma biomarker in upcoming clinical trials.

1 October 2012 in Autoimmunity Reviews
Verified
Journal Article
Closed access
RCRita Cascão
Rita Cascão
BVB. Vidal
B. Vidal
MRMaria Helena Raquel
Maria Helena Raquel
ACAna Neves Costa
Ana Neves Costa
NFNuno Figueiredo
Nuno Figueiredo
LMLuis Moita
Luis Moita

30 January 2014 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
RCRita Cascão
Rita Cascão
BVBruno Vidal
Bruno Vidal
MRMaria Helena Raquel
Maria Helena Raquel
ACAna Neves Costa
Ana Neves Costa
NFNuno Figueiredo
Nuno Figueiredo
LMLuis Moita
Luis Moita
Background. We have previously reported a continuous activation of caspase-1 and increased interleukin (IL)-1βlevels in early rheumatoid arthritis (RA). These observations raised the hypothesis that drugs targeting the IL-1βpathway, in addition to tumour necrosis factor (TNF), may be particularly effective for early RA treatment. We have recently identified gambogic acid as a promising therapeutic candidate to simultaneously block IL-1βand TNF secretion. Our main goal here was to investigate whether gambogic acid administration was able to attenuate inflammation in antigen-induced arthritis (AIA) rats.Methods. Gambogic acid was administered to AIA rats in the early and late phases of arthritis. The inflammatory score, ankle perimeter, and body weight were evaluated during the period of treatment. Rats were sacrificed after 19 days of disease progression and paw samples were collected for histological and immunohistochemical evaluation.Results. We found that inflammation in joints was significantly suppressed following gambogic acid administration. Histological and immunohistochemical evaluation of treated rats revealed normal joint structures with complete abrogation of the inflammatory infiltrate and cellular proliferation.Conclusions. Our results suggest that gambogic acid has significant anti-inflammatory properties and can possibly constitute a prototype anti-inflammatory drug with therapeutic efficacy in the treatment of inflammatory diseases such as RA.

6 January 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CGCarina S. S. Gomes-Santos
Carina S. S. Gomes-Santos
MIMaurice A. Itoe
Maurice A. Itoe
CACristina Afonso
Cristina Afonso
Ricardo HenriquesRicardo Henriques
Ricardo Henriques
RGRui Gardner
Rui Gardner
MMMaria M. Mota
Maria M. Mota
Plasmodium sporozoites are transmitted by Anopheles mosquitoes and infect hepatocytes, where a single sporozoite replicates into thousands of merozoites inside a parasitophorous vacuole. The nature of the Plasmodium-host cell interface, as well as the interactions occurring between these two organisms, remains largely unknown. Here we show that highly dynamic hepatocyte actin reorganization events occur around developing Plasmodium berghei parasites inside human hepatoma cells. Actin reorganization is most prominent between 10 to 16 hours post infection and depends on the actin severing and capping protein, gelsolin. Live cell imaging studies also suggest that the hepatocyte cytoskeleton may contribute to parasite elimination during Plasmodium development in the liver.

1 November 1996 in Plant Science
Verified
Journal Article
Closed access
MRMaria Helena Raquel
Maria Helena Raquel
M. Margarida OliveiraM. Margarida Oliveira
M. Margarida Oliveira